News

Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma

- Data demonstrate that administration of WTX-330 reached therapeutically relevant exposure levels of systemically delivered IL-12 prodrug with an improved…

2 years ago

ROSE LifeScience announces quality upgrade to top-selling Pure Laine Big Pleasures

HUNTINGDON, Quebec, June 25, 2024 (GLOBE NEWSWIRE) -- ROSE LifeScience Inc. (“ROSE”), a major Québec cannabis producer, distributor, and marketer,…

2 years ago

Fractyl Health to Present at Piper Sandler 2nd Annual Virtual Obesity Day

Company will discuss recent corporate updates, including compelling preclinical data from Rejuva® pancreatic gene therapy platform, which was named top…

2 years ago

Skye BioScience Participating in Piper Sandler Virtual Obesity Day

SAN DIEGO, June 25, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) ("Skye" or the "Company”), a clinical-stage biopharmaceutical…

2 years ago

New Book, ‘>100g/sqft: The New Cultivation Standard’ Reveals Secrets to Greater Yields, Lower Costs

Detailed lessons of industry veterans Chris O’Ferrell and Luca Boldrini are brought to life through gorgeous photography and vivid, hand-drawn…

2 years ago

SNL Creative and Iridia Announce Revolutionary Partnership to Enhance Medical Device Traceability; Showcasing at RAPID + TCT Show, Booth #2651

LOS ANGELES, June 25, 2024 (GLOBE NEWSWIRE) -- SNL Creative, a leader in additive manufacturing, and Iridia, a pioneer in…

2 years ago

Frontier Medicines Appoints Gerardo Ubaghs as Chief Financial Officer and Announces $20 Million Series C Extension

Gerardo Ubaghs brings high-profile global biopharma strategic and capital markets experience as newly appointed Chief Financial Officer (CFO)Company adds $20…

2 years ago

CVRx Announces Appointment of Robert Allen John as Chief Revenue Officer

MINNEAPOLIS, June 25, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced the…

2 years ago

Eckert & Ziegler Subsidiary Pentixapharm Receives Encouraging FDA Feedback to Initiate Phase III Trial with PentixaFor as Radiopharmaceutical Diagnostic in Primary Aldosteronism

WÜRZBURG, Germany, June 25, 2024 (GLOBE NEWSWIRE) -- Pentixapharm AG, a radiopharmaceutical development company wholly owned by Eckert & Ziegler…

2 years ago